Department of Pathology and Molecular Medicine
David Lillicrap has not added Biography.
If you are David Lillicrap and would like to personalize this page please email our Author Liaison for assistance.
Genetic basis of familial Meniere's disease.
The Journal of otolaryngology Feb, 2002 | Pubmed ID: 11883436
Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.
Thrombosis and haemostasis Mar, 2002 | Pubmed ID: 11916075
Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia.
Thrombosis and haemostasis Apr, 2002 | Pubmed ID: 12008949
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
Blood Aug, 2002 | Pubmed ID: 12149189
A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay.
Thrombosis and haemostasis Aug, 2002 | Pubmed ID: 12195715
The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.
Human gene therapy Sep, 2002 | Pubmed ID: 12228013
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Blood Mar, 2003 | Pubmed ID: 12406898
A survey of recommendations by gynecologists in Canada regarding oral contraceptive use in the perioperative period.
American journal of obstetrics and gynecology Dec, 2002 | Pubmed ID: 12501060
Gene expression: overview and clinical implications.
Vox sanguinis Aug, 2002 | Pubmed ID: 12617108
Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.
Blood Jul, 2003 | Pubmed ID: 12649144
Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.
Blood Sep, 2003 | Pubmed ID: 12738670
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
Blood Feb, 2004 | Pubmed ID: 14512318
Preclinical animal models for hemophilia gene therapy: predictive value and limitations.
Seminars in thrombosis and hemostasis Apr, 2004 | Pubmed ID: 15118932
A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of 2 nonadjacent exons.
Blood Nov, 2004 | Pubmed ID: 15226181
Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice.
Molecular therapy : the journal of the American Society of Gene Therapy Jul, 2004 | Pubmed ID: 15233948
Reliability and reproducibility of classification of children as "bleeders" versus "non-bleeders" using a questionnaire for significant mucocutaneous bleeding.
Journal of pediatric hematology/oncology Aug, 2004 | Pubmed ID: 15284585
Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.
Journal of molecular modeling Aug, 2004 | Pubmed ID: 15322948
Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
The journal of gene medicine Dec, 2004 | Pubmed ID: 15493040
Cell type-specific regulation of von Willebrand factor expression by the E4BP4 transcriptional repressor.
Blood Feb, 2005 | Pubmed ID: 15498853
Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease.
Blood Jun, 2005 | Pubmed ID: 15705799
Aminoglycoside suppression of nonsense mutations in severe hemophilia.
Blood Nov, 2005 | Pubmed ID: 16051741
Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells.
Stem cells (Dayton, Ohio) Apr, 2006 | Pubmed ID: 16339997
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
Blood Jul, 2006 | Pubmed ID: 16522813
Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.
Seminars in thrombosis and hemostasis Jun, 2006 | Pubmed ID: 16804830
Genetic testing for von Willebrand disease: the Canadian experience.
Seminars in thrombosis and hemostasis Jul, 2006 | Pubmed ID: 16862529
The role of immunomodulation in the management of factor VIII inhibitors.
Hematology. American Society of Hematology. Education Program , 2006 | Pubmed ID: 17124093
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.
Blood Apr, 2007 | Pubmed ID: 17148587
The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.
Blood Jan, 2007 | Pubmed ID: 17190853
Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF.
Blood Mar, 2007 | Pubmed ID: 17312004
Theories of blood coagulation.
Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses May-Jun, 2007 | Pubmed ID: 17475978
Von Willebrand: the scientist, the disease, the factor, and the treatment.
Thrombosis research , 2007 | Pubmed ID: 17482240
Von Willebrand disease - phenotype versus genotype: deficiency versus disease.
Thrombosis research , 2007 | Pubmed ID: 17490730
Distinguishing between non-identical twins: platelet type and type 2B von Willebrand disease.
British journal of haematology Sep, 2007 | Pubmed ID: 17608761
Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Stem cells (Dayton, Ohio) Oct, 2007 | Pubmed ID: 17615271
Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.
Blood Jan, 2008 | Pubmed ID: 17978172
Von Willebrand disease.
Pediatric clinics of North America Apr, 2008 | Pubmed ID: 18381092
Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.
Blood Jan, 2009 | Pubmed ID: 18815284
Coagulation factors--molecular attributes and their clinical impact.
Thrombosis research , 2008 | Pubmed ID: 18929520
Extending half-life in coagulation factors: where do we stand?
Thrombosis research , 2008 | Pubmed ID: 18929522
ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor.
British journal of haematology Nov, 2008 | Pubmed ID: 18986390
The role of molecular genetics in diagnosing von Willebrand disease.
Seminars in thrombosis and hemostasis Sep, 2008 | Pubmed ID: 19085649
Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
Blood Jul, 2009 | Pubmed ID: 19411636
A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
Blood Jul, 2009 | Pubmed ID: 19458355
[Application studies on the gene diagnosis and carrier detection of hemophilia A by using polymerase chain reaction-conformation sensitive gel electrophoresis].
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics Aug, 2009 | Pubmed ID: 20017302
Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.
Blood Jun, 2010 | Pubmed ID: 20371742
Characterization of viability and proliferation of alginate-poly-L-lysine-alginate encapsulated myoblasts using flow cytometry.
Journal of biomedical materials research. Part B, Applied biomaterials Aug, 2010 | Pubmed ID: 20586078
Improvements in factor concentrates.
Current opinion in hematology Sep, 2010 | Pubmed ID: 20613509
Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.
Blood Nov, 2010 | Pubmed ID: 20696945
Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B.
Biomaterials Jan, 2011 | Pubmed ID: 20864158
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.
Blood Dec, 2010 | Pubmed ID: 20876851
Challenges and innovations in the treatment of bleeding disorders.
Thrombosis research Jan, 2011 | Pubmed ID: 21056903
Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease.
Thrombosis research Feb, 2011 | Pubmed ID: 21094983
Early intraoperative blood collection does not affect complete blood counts, von Willebrand factor or factor VIII levels in normal children.
Journal of pediatric hematology/oncology Jan, 2011 | Pubmed ID: 21178707
A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
Molecular therapy : the journal of the American Society of Gene Therapy Apr, 2011 | Pubmed ID: 21285959
Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study.
Thrombosis and haemostasis Mar, 2011 | Pubmed ID: 21301777
Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.
Blood Apr, 2011 | Pubmed ID: 21346256
Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease.
Pediatric blood & cancer Dec, 2011 | Pubmed ID: 21425451
The diagnosis and management of von Willebrand disease in Canada.
Seminars in thrombosis and hemostasis Jul, 2011 | Pubmed ID: 22102195
Solulin increases clot stability in whole blood from humans and dogs with hemophilia.
Blood Apr, 2012 | Pubmed ID: 22234684
von Willebrand disease: Clinical and laboratory lessons learned from the large von Willebrand disease studies.
American journal of hematology Feb, 2012 | Pubmed ID: 22389132
The World Federation of Hemophilia and research.
Haemophilia : the official journal of the World Federation of Hemophilia Jul, 2012 | Pubmed ID: 22726078
A complex substitute: antibody therapy for hemophilia.
Nature medicine Oct, 2012 | Pubmed ID: 23042345
The future of hemostasis management.
Pediatric blood & cancer , 2013 | Pubmed ID: 23109347
Alloantibodies in von Willebrand disease.
Blood Aug, 2013 | Pubmed ID: 23297130
The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.
Blood Jun, 2013 | Pubmed ID: 23529928
Introduction to a series of reviews on cancer-associated thrombotic disease.
Blood Sep, 2013 | Pubmed ID: 23798712
The Canadian "National Program for hemophilia mutation testing" database: a ten-year review.
American journal of hematology Dec, 2013 | Pubmed ID: 23913812
Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A.
Nature medicine Oct, 2013 | Pubmed ID: 24037092
von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.
Blood Nov, 2013 | Pubmed ID: 24065240
Genetic sequence analysis of inherited bleeding diseases.
Blood Nov, 2013 | Pubmed ID: 24124085
von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.
Hematology. American Society of Hematology. Education Program , 2013 | Pubmed ID: 24319188
A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A.
PloS one , 2013 | Pubmed ID: 24358271
Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
Blood Jun, 2014 | Pubmed ID: 24829206
FVIII stabilization: VWF D'D3 will do.
Blood Jul, 2014 | Pubmed ID: 25035147
Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation.
Blood Sep, 2014 | Pubmed ID: 25051961
Syntaxin-binding protein 5 exocytosis regulation: differential role in endothelial cells and platelets.
The Journal of clinical investigation Oct, 2014 | Pubmed ID: 25244090
Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.
Journal of pediatric hematology/oncology May, 2015 | Pubmed ID: 25411864
Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
Haematologica Feb, 2015 | Pubmed ID: 25638804
Introduction to a series of reviews on inherited bleeding disorders.
Blood Mar, 2015 | Pubmed ID: 25712995
Journal of Thrombosis and Haemostasis. Special Issue: State of the Art 2015. Preface.
Journal of thrombosis and haemostasis : JTH Jun, 2015 | Pubmed ID: 26149009
To clear or to fear: An innate perspective on factor VIII immunity.
Cellular immunology Mar, 2016 | Pubmed ID: 26547364
Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII.
Molecular therapy. Methods & clinical development , 2015 | Pubmed ID: 26636112
War and peace: Factor VIII and the adaptive immune response.
Cellular immunology Mar, 2016 | Pubmed ID: 26676073
Foreword.
European journal of haematology Dec, 2015 | Pubmed ID: 26679391
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.
Cellular immunology Mar, 2016 | Pubmed ID: 26775174
Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
Blood May, 2016 | Pubmed ID: 26862110
Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A.
Blood Jun, 2016 | Pubmed ID: 27034428
Gene Therapy for Coagulation Disorders.
Circulation research Apr, 2016 | Pubmed ID: 27126652
How much do we really know about von Willebrand disease?
Current opinion in hematology Sep, 2016 | Pubmed ID: 27428891
Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.
Blood transfusion = Trasfusione del sangue Jul, 2016 | Pubmed ID: 27483487
Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
Blood Oct, 2016 | Pubmed ID: 27587878
Summary report of the First International Conference on inhibitors in haemophilia A.
Blood transfusion = Trasfusione del sangue Nov, 2016 | Pubmed ID: 27893354
Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A.
American journal of hematology Jun, 2017 | Pubmed ID: 28249352
Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.
Blood Jun, 2017 | Pubmed ID: 28432221
Bispecific Antibody Therapy in Hemophilia.
The New England journal of medicine Jul, 2017 | Pubmed ID: 28691560
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유